QuoTrend
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNews
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNewsMore
⌘K
Help
QuoTrend
PAGEHome
HomePricingContactHelpTermsPrivacy
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
© 2026 QuoTrend
Screen

PRAX

QT54Praxis Precision Medicines, Inc.
NASDAQ·Healthcare·Biotechnology·USA
Latest market price
282.31
+12.30+4.56%
OverviewShort InterestFilings
PRAXQT54Praxis Precision Medicines, Inc.·NASDAQ
OverviewShort InterestFilings
282.31+4.56%
TA
Loading chart...
Screen all →
VRTX-1.60%$451.63REGN+0.33%$609.94ARGX-1.63%$877.72ALNY-1.64%$278.09RVMD+3.31%$162.99MRNA+3.50%$63.96UTHR-2.70%$536.59BNTX-1.44%$90.89
Snapshot
Index-P/E-EPS (ttm)
-
Insider Own-
Shs Outstand27.88M
Perf Week13.84%
Market Cap5.71BForward P/E-EPS next Y-10.92Insider Trans0.00%Shs Float-Perf Month-11.95%
Enterprise Value5.17BPEG1.08EPS next Q-3.68Inst Own-Short Float-Perf Quarter-5.11%
Income-239184266.00P/S0.00EPS this Y-Inst Trans-Short Ratio-Perf Half Y2.84%
Sales-P/B5.53EPS next Y28.25%ROA-22.36%Short Interest-Perf YTD-4.22%
Book/sh15.03P/C-EPS next 5Y-ROE-43.02%52W High366.54 -22.98%Perf Year549.59%
Cash/sh12.63P/FCF-EPS past 3/5Y-ROIC-25.32%52W Low37.19 659.10%Perf 3Y-
Dividend Est.-EV/EBITDA-15.85Sales past 3/5Y-Gross Margin0.00%Volatility4.24% 5.10%Perf 5Y-
Dividend TTM-EV/Sales0.00EPS Y/Y TTM-30.95%Oper. Margin0.00%ATR (14)20.47Perf 10Y-
Dividend Ex-Date-Quick Ratio15.88Sales Y/Y TTM-Profit Margin0.00%RSI (14)47.09Recom2.15
Dividend Gr. 3/5Y-Current Ratio15.88EPS Q/Q2.74%SMA20-3.12%Beta0.52Target Price584.00
Payout0.00%Debt/Eq0.00Sales Q/Q-SMA50-10.67%Rel Volume1.50Prev Close270.01
Employees116LT Debt/Eq0.01EarningsAug 03SMA20015.08%Avg Volume452.74KPrice282.31
IPO DateOct 16, 2020Option/ShortYes / YesEPS/Sales Surpr.10.61% -Net Debt/EBITDA1.64Volume680,690Change4.56%
Analyst Ratings
DateActionAnalystRatingTarget
Jun-17-26InitiatedRBC CapitalOutperform$449
Jun-02-26ReiteratedTruist Financial$715 → $616
Jun-02-26ReiteratedRobert W. Baird$433 → $400
Jun-02-26ReiteratedH.C. Wainwright$1.00 → $1201
Jun-02-26ReiteratedWedbushUnderperform$166 → $162
Jun-02-26ReiteratedDeutsche BankBuy$420 → $374
Jun-02-26ReiteratedOppenheimerOutperform$750 → $650
Jun-02-26ReiteratedBTIGBuy$843 → $810
May-26-26ReiteratedH.C. Wainwright$340 → $1245
May-13-26ReiteratedTruist Financial$700 → $715
Latest News
Jun-18-26
Jun-18-2609:43AM
RBC Capital Initiates Coverage On Praxis Precision Medicine with Outperform Rating, Announces Price Target of $449Benzinga
Jun-15-26
Jun-15-2603:11AM
Praxis Precision Medicines (PRAX) Stock After Mixed POWER1 Trial Results How Does The Valuation Stack UpYahoo
Jun-11-26
Jun-11-2610:20AM
BTIG Reaffirms Buy Rating for Praxis Precision Medicines (PRAX)Yahoo
Company
Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
Total Revenue092
Upgrade your experience to unlock full historical data
Cost of Goods Sold Incl. D&A015287
Gross Profit0-144-84
Selling, General and Administrative Excl. Other595642
Research and Development26715287
Other Operating Expense0-152-87
Operating Income-326-200-126
Interest Expense
000
Unusual Expense
———
Non-Operating Income (Expense)-23-17-3
Net Income Before Taxes-303-183-123
Income Taxes
000
Consolidated Net Income-303-183-123
Net Income From Continuing Operations-303-183-123
Net Income-303-183-123
EPS (Recurring)-13.48-10.21-18.69
EPS (Basic, Before Extraordinaries)-13.48-10.21-18.69
EPS (Diluted)-13.48-10.21-18.69
EBITDA-303-182-123
Other After Tax Adjustments
———
Stock Option Compensation Expense
———
Price To Earnings Ratio
———
Price To Sales Ratio
———
Gross Margin—-1,600.00-4,200.00
Operating Margin—-2,222.22-6,300.00
Net Margin—-2,033.33-6,150.00
Shares Outstanding23187
Market Capitalization6,779——
Operating Lease Expense
———
Insider Trading Volume
$306.54$280.77$255.00$229.23$203.45● Close Price0.00M8.30M16.60M24.90M33.20MUSD Trades VolumeJunJulAugSepOctNovDec2026FebMarAprMayJun
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Nemiroff AlexGeneral Counsel and SecretaryNov 20 '25Option Exercise73.7650,2603,707,06445,962Nov 21 12:00 AM
Nemiroff AlexGeneral Counsel and SecretaryNov 20 '25Sale193.0925,1304,852,25620,832Nov 21 12:00 AM
Mastrocola LaurenPrincipal Accounting OfficerNov 20 '25Option Exercise61.1227,2001,662,51624,042Nov 21 12:00 AM
Mastrocola LaurenPrincipal Accounting OfficerNov 20 '25Sale192.0813,6002,612,24410,442Nov 21 12:00 AM
Adage Capital Management, L.P.10% OwnerOct 16 '25Sale105.76313,91033,198,1242,060,175Oct 17 12:00 AM
MITCHELL DEAN JDirectorSep 24 '25Option Exercise39.5124,502967,98417,251Sep 25 12:00 AM
Nemiroff AlexGeneral Counsel and SecretaryNov 14 '24Option Exercise56.9415,166863,55228,817Nov 15 12:00 AM
Mastrocola LaurenPrincipal Accounting OfficerNov 14 '24Sale81.785,188424,3185,613Nov 15 12:00 AM
Nemiroff AlexGeneral Counsel and SecretaryNov 14 '24Sale80.208,239660,82710,301Nov 15 12:00 AM
Mastrocola LaurenPrincipal Accounting OfficerNov 14 '24Option Exercise56.948,748498,11216,626Nov 15 12:00 AM
DeSimone JillDirectorOct 05 '23Buy1.7514,50025,37514,500Oct 10 12:00 AM
Souza MarcioChief Executive OfficerJun 27 '23Buy1.0610,00010,58745,002Jun 27 12:00 AM
Kelly Timothy EdwinChief Financial OfficerMar 24 '23Buy0.8716,00013,99646,416Apr 06 12:00 AM
MITCHELL DEAN JDirectorMar 24 '23Buy0.8450,00041,81575,000Mar 27 12:00 AM
Souza MarcioChief Executive OfficerMar 23 '23Buy0.8670,00260,367226,299Mar 27 12:00 AM
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR